Saltar al contenido
Merck

Meloxicam decreases the migration and invasion of CF41.Mg canine mammary carcinoma cells.

Oncology letters (2017-08-07)
María P Iturriaga, Rodolfo Paredes, Jose I Arias, Cristian G Torres
RESUMEN

Cyclooxygenase (COX)-2 expression is positively correlated with malignant features in canine mammary carcinomas. Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit COX activity and may therefore possess anticancer effects. Meloxicam is an NSAID that is widely used in human and veterinary medicine. High concentrations of meloxicam have been reported to be antitumorigenic